06 November 2018
Visiongain has launched a new pharma report: Pharma Wholesale and Distribution Market Forecasts 2018-2028: Branded Drugs, Generic Drugs, US, China, Japan, Germany, France, Brazil, Italy, Spain, UK, India, Russia, RoW.
The pharmaceutical wholesale and distribution market is influenced by the play of a variety of factors; it has both strengths and weaknesses and faces both opportunities and threats. The market will be driven by an overall increased demand for pharmaceuticals owing to the growing ageing population of developed countries and the increasing access to healthcare of the expanding middle class in the emerging economies.
The lead analyst of the report commented "Disease prevalence is expected to increase in all pharmaceutical markets, increasing sales of prescription drugs worldwide. Distributing increased volumes of drugs will benefit wholesalers through increased revenues. The increased sales volume will be particularly noticeable in emerging markets, such as China, India and Brazil. There, increased wealth of the population and further urbanisation will lead to changes in disease patterns, as cancer and cardiovascular diseases, already two of the leading causes of death in developed markets, become more prominent. Wholesalers involved in specialty distribution, such as for cancer treatments, will benefit from those trends."
Leading companies featured in the report include Alfresa Holdings, AmerisourceBergen, Cardinal Health, McKesson, Medipal, PHOENIX Group, Shanghai Pharma, SINOPHARM, Suzuken, Walgreens Boots Alliance
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.